Impact of influenza vaccine-modified infectivity on attack rate, case fatality ratio and mortality.

Clicks: 407
ID: 94959
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #8 of 23 articles by views in Journal of theoretical biology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Generally, vaccines are designed to provide protection against infection (susceptibility), disease (symptoms and transmissibility), and/or complications. In a recent study of influenza vaccination, it was observed that vaccinated yet infected individuals experienced increased transmission levels. In this paper, using a mathematical model of infection and transmission, we study the impact of vaccine-modified effects, including susceptibility and infectivity, on important epidemiological outcomes of an immunization program. The balance between vaccine-modified susceptibility, infectivity and recovery needed in preventing an influenza outbreak, or in mitigating the health outcomes of the outbreak is studied using the SIRV-type of disease transmission model. We also investigate the impact of influenza vaccination program on the infection risk of vaccinated and non-vaccinated individuals.
Reference Key
nah2020impactjournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal Journal of theoretical biology
Year 2020
DOI
S0022-5193(20)30040-0
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.